A detailed history of Rafferty Asset Management, LLC transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 652,966 shares of IOVA stock, worth $4.82 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
652,966
Previous 724,179 9.83%
Holding current value
$4.82 Million
Previous $5.81 Million 5.58%
% of portfolio
0.02%
Previous 0.02%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$7.28 - $11.9 $518,430 - $847,434
-71,213 Reduced 9.83%
652,966 $6.13 Million
Q2 2024

Aug 13, 2024

BUY
$7.78 - $14.19 $1.09 Million - $1.99 Million
140,068 Added 23.98%
724,179 $5.81 Million
Q1 2024

May 13, 2024

SELL
$7.59 - $17.47 $5.04 Million - $11.6 Million
-663,404 Reduced 53.18%
584,111 $8.66 Million
Q4 2023

Feb 13, 2024

SELL
$3.3 - $8.89 $820,561 - $2.21 Million
-248,655 Reduced 16.62%
1,247,515 $10.1 Million
Q3 2023

Nov 13, 2023

BUY
$4.44 - $8.79 $1.97 Million - $3.9 Million
443,249 Added 42.1%
1,496,170 $6.81 Million
Q2 2023

Aug 11, 2023

SELL
$5.36 - $9.06 $227,896 - $385,213
-42,518 Reduced 3.88%
1,052,921 $7.41 Million
Q1 2023

May 11, 2023

SELL
$5.53 - $8.22 $388,532 - $577,528
-70,259 Reduced 6.03%
1,095,439 $6.69 Million
Q4 2022

Feb 13, 2023

BUY
$5.62 - $10.0 $3.07 Million - $5.47 Million
547,013 Added 88.42%
1,165,698 $7.45 Million
Q3 2022

Nov 14, 2022

BUY
$9.53 - $13.11 $1.51 Million - $2.08 Million
158,605 Added 34.47%
618,685 $5.93 Million
Q2 2022

Aug 12, 2022

BUY
$6.38 - $18.33 $346,893 - $996,638
54,372 Added 13.4%
460,080 $5.08 Million
Q1 2022

May 13, 2022

BUY
$12.38 - $19.1 $1.49 Million - $2.3 Million
120,202 Added 42.1%
405,708 $6.76 Million
Q4 2021

Feb 10, 2022

BUY
$16.55 - $27.63 $2.46 Million - $4.11 Million
148,649 Added 108.62%
285,506 $5.45 Million
Q3 2021

Nov 10, 2021

BUY
$20.35 - $26.63 $521,407 - $682,313
25,622 Added 23.03%
136,857 $3.38 Million
Q2 2021

Aug 10, 2021

BUY
$16.33 - $33.07 $247,987 - $502,201
15,186 Added 15.81%
111,235 $2.89 Million
Q1 2021

May 10, 2021

BUY
$28.67 - $52.59 $2.22 Million - $4.07 Million
77,386 Added 414.65%
96,049 $3.04 Million
Q4 2020

Feb 10, 2021

SELL
$28.04 - $50.26 $1.23 Million - $2.21 Million
-43,929 Reduced 70.18%
18,663 $866,000
Q3 2020

Nov 13, 2020

BUY
$27.75 - $36.3 $838,799 - $1.1 Million
30,227 Added 93.39%
62,592 $2.06 Million
Q2 2020

Aug 07, 2020

BUY
$27.21 - $41.0 $550,648 - $829,717
20,237 Added 166.86%
32,365 $888,000
Q1 2020

May 15, 2020

SELL
$19.54 - $38.85 $1.78 Million - $3.53 Million
-90,862 Reduced 88.22%
12,128 $363,000
Q4 2019

Feb 10, 2020

SELL
$17.95 - $29.41 $2.49 Million - $4.08 Million
-138,670 Reduced 57.38%
102,990 $2.85 Million
Q3 2019

Nov 14, 2019

BUY
$17.99 - $26.0 $2.61 Million - $3.78 Million
145,274 Added 150.72%
241,660 $4.4 Million
Q2 2019

Aug 09, 2019

SELL
$9.78 - $24.52 $509,058 - $1.28 Million
-52,051 Reduced 35.07%
96,386 $2.36 Million
Q1 2019

May 15, 2019

BUY
$8.41 - $11.26 $1.25 Million - $1.67 Million
148,437 New
148,437 $1.41 Million

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.16B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.